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ABSTRACT    
 
 
Background & Objectives:  
 
Seroma, is the most frequent post operative complication after breast cancer 
surgery/modified radical mastectomy (MRM), developing in approximately 30% 
of cases. The pathophysiology and mechanism of seroma formation in breast 
cancer surgery remains controversial and not fully understood, as little attention 
has been paid in the literature to etiologic factors. To prevent seroma formation, it 
is important to estimate individual risk of seroma formation.  
 
Aim of the study : 
 To establish an association between various risk factors of seroma 
formation and to know whether the risk factors act independently or by synergism.  
 
Methods: 
 Patients with breast cancer undergoing Modified Radical Mastectomy were 
included in the study. The proportions were compared using Chi-square test of 
significance and the student „t‟ est w as used to determ ine the statistical 
difference. The data was analyzed using SPSS package.  
 
Results:  
16 out of  50 patients, accounting for 32 percent, developed seroma. compared to 
patients without seroma formation. 15 of 16 patients who had developed seroma 
were hypertensive, accounting for 68.2%, pvalue was significant 0.001. The mean 
BMI  in seroma patients was 26.16 +1.79(21.30-28.40) , p value was significant 
0.001. The mean drain output on pod 1 was 200.3+ 36.44 in seroma group, p 
value was 0.032. Mean drain removal day was 15.50 + 1.82 (13-19), p value was 
0.036 in seroma group. Other variables studied had no statistical significance with 
respect to seroma formation.  
Conclusion: The factors influencing seroma formation following modified 
radical mastectomy for carcinoma breast were found to be Hypertension and BMI , 
having a significant association for seroma formation . 
 
  
  
1EVOLUTION OF SURGICAL TECHNIQUE
Hippocrates : associated breast cancer with cessation of menstruation, Leon ides
is acknowledged to be the 1 st operative treatment for breast malignancy.
Andreas Vesalius (b. 1514), Flemish physician, advised  mastectomy for breast
cancer and practiced the use of sutures  than cautery to control bleeding.
Servetus, advised that the underlying  muscles ( pectoralis major & minor )  to be
removed as well as the axillary glands.
Wilhelm Fabry (b. 1560), the, Father of German Surgery, devised an instrument
for mastectomy as shown in figure 1.
Mitchell Banks of Liverpool, in 1877  practised removal of axillary glands in all
cases of  breast cancer.
Dr.  Joseph  Pancoast   ,was first to show  enblock  removal of axillary glands as
shown in figure 2
The rationale for the Halsted radical mastectomy was largely to achieve
locoregional  control of the breast malignancy.
 In contrast to the Halsted radical mastectomy, the modified radical
mastectomy defines a surgery of complete breast removal, with the inclusion of the
tumour, overlying skin, and axillary lymphatics, with preservation of the pectoralis
major muscle.
2Murphy  in 1912 had stopped  Halsted radical mastectomy and started  preserving
pectoral muscles. This  was based on the experiences of Bryant .
The Consensus Development Conference on the management of breast
malignancy in 1979 stated that the modified radical mastectomy was the standard
of treatment for women with stages I and II breast cancer4
Figure 1: Mastectomy instruments of Fabry von
Hilden in late sixteenth century.
3Figure 2: Mastectomy (1844) of Dr. Joseph Pancoast in the preanesthetic and
pre antiseptic era. En bloc removal with axillary lymphatic drainage
4INTRODUCTION
The term breast is derived from latin word mamma ( cf. mammal from latin
mammalis “ of the breast “ ). Breast are modified  sudoriferous glands , composed
of glandular , adipose , and connective tissues .
Breast cancer is the commonest malignancy in women affecting one out of
eight women worldwide and ranks among the top ten causes of death in women.1,2
more than a million cases are diagnosed  each year , rise in incidence is due to
increased life span , life style changes and improved survival from other illness,
and better investigation to diagnose early breast malignancy. It  forms thirty three
percent of all female cancers and for twenty percent  of cancer related deaths in
women .  Almost  half of all patients with a palpable primary breast cancer will
have lymph node metastases at presentation compared with only one fifth of those
with a non palpable cancer detected on mammography.2  In majority of patients
with breast malignancy, excision of the tumour with (ALND) remains the standard
treatment for invasive breast cancer3
Metastases in axillary lymph nodes is the most  determinant of prognostic
factor in patients with primary breast malignancy.
Almost all patients develop patches of numbness or paraesthesia and many
patients develop reduced shoulder mobility and chronic lymphoedema.4 Seroma is
an abnormal accumulation of serous fluid in the dead space of axilla, the breast
following breast-conserving(BCT) surgery and is the commonest sequel. The
5incidence of seroma formation varies between 5 and eighty five per cent.4, 9, 14-20
Seroma  can  increase the morbidity , prolong the hospital stay , need for multiple
aspirations , wound gaping , erythema , delay the chemotherapy cycles.4
The type of surgery, the operating surgeon, preoperative radiation or
chemotherapy, the amount of post operative physical activity, use of electrocautery,
use of closed su ction drains and closure of dead space have been implicated as
potential factors influencing the likelihood of seroma formation.4-7
Constant chest wall movement due to respiration and shoulder use creates
shearing forces that delay flap adhesion.5 For this, several techniques of flap
fixation or wound drainage, limitation of postoperative shoulder movement and the
use of adhesive glue have been investigated to improve primary healing and
minimize seroma formation.6 To reduce the incidence of seroma  formation , it is
essential  to estimate individual risk for seroma formation , and future trials should
be aimed at identifying predictive variables and thus reduce the incidence of
seroma .
6REVIEW OF LITERATURE
DEFINITION
There are various definitions for seroma as published in many article ,Classe
et al7 defined axillary seroma as a palpable fluid accumulation causing discomfort
and needing aspiration.
Woodworth et al8 during a retrospective analysis defined seroma as a
clinically identifiable collection of serous fluid within a surgical cavity. They
treatedseromas with serial aspirations until no further fluid collections are detected.
Nadkarni et al9 defined the presence of postoperative seroma as a need to
aspirate serous  fluid  from the axillary  cavity more than once,or, 2 or more times
after removal of the axillary drain.
Benjasirichai et al11defined postoperative seroma as any collection in the
axilla that was detected by ultrasonography 2 weeks after the patient was
discharged.
Hashemi et al10 defined axillary seroma as any clinically apparent fluid
collection in the axilla or under skin flaps .
7SEROMA INCIDENCE
Seroma  frequency varies between  5 & 85%.3, 9, 14-20
Table 1: SEROMA INCIDENCE
Authors Study Type Surgery Patients(n)
Incidence
(%)
Chen et al, 199815 RCT MRM,BCS 40 4.8
Gupta et al, 200116 RCT MRM 121 48
Purshotham et al,
200217
RCT MRM,BCS 375 51
Jain et al, 200418 RCT MRM,BCS 116 26
Lumachi et al,
200419
RCT MRM,BCS 92 40
Unalp et al, 200720 Retrospective MRM,BCS 119 14.3
Nadkarni et al,
20079
RCT MRM,BCS 160 84.7
8PATHOPHYSIOLOGY
Seromas are collection of  lymph exudates or ‘‘serum’’ in cavities,
invariably due to surgery and healing process of inflammation.14,22 . Continuous
chest wall and shoulder movements disrupt the flap opposition to chest wall.24
Bonnema et al25 showed that the fibrinogen level in seroma was very low
compared with plasma on day 1 but on day 5 and 10 post operatively it was
virtually undetectable,and that peripheral lymph does not clot and contains only a
trace amount of fibrinogen.
Oertli et al14presumed  that fibrinolytic process leads to seroma formation.
Tadych and Donegan21believed that seroma is due to the leakage of lymph from
disrupted lymphatics in the axilla.  Extensive manipulation and  to the tissues
creating a raw area in (MRM) leads to seroma formation from severed blood
vessels & lymphatics and compared to (BCT) which produces less seroma.22  Ideal
closure  of wound will reduce lymph spillage& serum ooze, will approximate flaps
to the underlying structures appropriately thus eliminating the dead space.3
FACTORS AFFECTING SEROMA FORMATION
Seroma is considered to be a side effect of surgery than a complication ,it
can lead to significant morbidity like wound dehiscence , delay in initiation of
adjuvant chemotherapy .
9Kuroi et al28, review included one Meta analysis, 51 RCTs, 7 prospective
&retrospective. They divided the risk factors for seroma formation into four
categories: Patient and tumor characteristics, Surgical Factors, Post operative
management, Non Surgical Modalities.
PATIENT AND DISEASE FACTORS
The incidence of seroma has been shown to correlate with patient’s
age,breast size, and hypertension,presence of malignant nodes in the axilla,number
of malignant nodes,previous surgical biopsyand use of heparin.19, 28, 29patients who
received chemotherapy before surgery had problems of wound healing and
increased seroma occurence.8
Gonzalez  et  al27observed  that neo adjuvant chemotherapy did not affect
seroma occurrence.
Kumar et al29 found a significant association b/w BW and HTN with
seroma but no association between nodal status or positivity of lymph nodes,
hormone receptor status and stage with seroma formation. there was no corelation
with other factors such as ,DM , size of the breast, grade of the tumour , side
10
Table 2:  Association of Patient and Disease factors with Seroma formation28
Patient Factors Association Disease Factors Association
Age Inconclusive Disease Stage ?
Menstrual Status ? LN Status ?
Side/Tumor location ? Tumor size Inconclusive
Hypertension ? Histological type ?
Diabetes ? Grade ?
Body weight ? Specimen size/weight ?
Anemia ?
Pathological Tumor
size
?
Breast size ? LN positivity Inconclusive
NAC/ Prior Biopsy/RT ?
Hormone Receptor
Status
?
BMI/Obesity Inconclusive
? = Increases seroma formation
?  = No definite association
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SURGICAL FACTORS
Type of Surgery
Seroma  incidence  is  lower  after  BCS  than  MRM.19,27 sentinel lymph node
biopsy has prevented larger dissections thus in BCS seroma is less.
Woodworth et al8proved that reconstruction following MRM decreased
seroma formation. There was no correlation seen with preserving pectoral
fascia 30
AXILLARY DISSECTION
Time and again large number of studies have proved there is no corelation
with number of axillary lymph nodes removed and seroma .27, 31-33
Purushotham et al32  in  the  RCT involving 298 patients with early breast
cancer  who were clinically node negative, patients were randomly allocated to
undergo ALND (control group) or SLNB followed by ALND if subsequently found
to be lymph node positive (study group). ).   (SLNB)  is  associated  with  very  less
seroma  & morbidity than  ALND.
Its been demonstrated that a long procedure time and diagonal skin incision
as compared to vertical skin incision increased seroma .28,34
12
Table 3: Association of operational factors with seroma formation28
Increases
Seroma
Decreases
Seroma
No Association
Inconclusive
Evidence
Extended RM
Ultrasonic
Dissection
Extent of LN
dissection
Surgeon
Diagonal
Skin Incision
Immediate Breast
Reconstruction
Removal of pectoral
Fascia
Pressure Garment/
Compression
dressing
Operation
time
Suture Flap
fixation
Type of Anesthesia MRM Vs BCS
Electrocautery SLNB Vs ALND Laser Scalpel Skin graft
Adhesive Glue
Blood loss
SURGICAL TECHNIQUE/ INSTRUMENT
Tissue handling & dissection play a vital role in determining the occurrence
of seroma. It islearnt that proper tissue handling and to minimize the bleeding and
trauma to lymphatics can prevent seroma formation.3
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Electro cautery has its own advantages of short duration, with less  amount of blood
loss but has its own problems of wound complications & seroma as shown by
Porter  et  al35 and Keogh  et  al36 through RCTs. However, studies by Unalp and
Onal20 and  Nadkarni  et al9 have failed to show any statistically significant
difference in seroma formation between knife dissection and electrocautery
dissection.Irshad and Campbell37said harmonic scalpel reduced seroma
formation.
Lumachi et al19 randomized ninety-two women to undergo axillary
dissection by either using ultrasound scissors (Group A, 45 patients) or not (Group
B, 47 patients). Twenty-eight patients developed  wound seroma. In patients with
ultrasonic dissection drains were removed  earlier .
Kontos et al39prospectively randomized 32 patients who underwent
modified radical mastectomy to either HS or electrocautery (EC). First 48 h
drainage, total drained volume, aspirated volume, complications and required
analgesia were comparable in the two groups and concluded that no significant
reduction in seroma formation or wound complications and pain could be found
with the use of HS.
Kerin et al41 failed to show the difference in postoperative seroma drainage
between argon-enhanced electro surgery and conventional diathermy.
14
Table 4: comparative studies between ,
electrocautery and Ultrasonic dissection
Authors
Type of
Study
Total
Patients
Surgical Technique
(No. of patients with
seroma)
P value
Porter et al,
199835
RCT 80 EC(38) Vs Sharp(13) 0.01
Galatius et
al, 200342
Comparativ
e
59 Sharp(69) Vs US(67) NS
Lumachi et
al, 200419
RCT 92 Sharp(42) Vs US(20) NS
Nadkarni et
al, 20079
RCT 158 EC(68) Vs Sharp(59) NS
Unalp et al,
200720
Retrospecti
ve
119 EC(12) Vs Sharp(5) NS
Sharp  = dissection with sharp scissors Laser = dissection with argon laser
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DRAINS
Frequently drains are used after breast cancer surgery with the understanding
that it will reduce seroma formation. The mechanism proposed is that the suction
helps skin flaps to adhere to the underlying structure & axilla sealing off all leaking
lymphatics. And thus, may facilitate wound healing, decrease wound infection, flap
necrosis and prevent seroma formation.3
Drain Vs. No Drain
Talbot and Magarey43 evaluated prospectively three groups of consecutive
patients with breast cancer having axillary lymph node clearance. In the delayed
removal group, 30 patients had total or partial mastectomy with axillary dissection,
followed by closed suction drainage until the fluid output was < 50 mL in 24 h. In the
early removal group, 30 patients had the same procedures, except that the drains were
removed 2 days postoperatively, irrespective of the volume of drainage. In the ‘no
drain’ group, 30 patients underwent partial mastectomy and axillary clearance without
inserting any drain. Patients without drain needed more serial aspiration.The
aspiration in each group being 2.1, 2.9, and 3.9, respectively. The observed that
earlier removal of drain following ALND got discharged earlier with not much of
wound  infections.
Jain et al18randomized 116 patients undergoing MRM to receive suction
drainage or  no drain . There was a significant reduction in hospital stay and
postoperative pain scores in patients who did not have a drain. Following
16
mastectomy without a drain, the use of fibrin sealant reduced seroma formation(P<
0.012). They observed  that drains did not prevent seroma formation.
Single vs many  Drains
Terrell and Singer in 199244randomized 84 women undergoing (MRM). 37
patients had one axillary drain and 47 had two drains placed postoperatively, one in
the axilla and the other beneath the pectoral flaps. The average total drainage was
870.4 mL per patient in the group with single drain and 997.4 mL per patient in the
group with two drains and the overall complication rate was 35.0 percent and 31.9
for single drain group and two drain groups respectively. These differences did not
reach statistical significance. They concluded that use of a single axillary drain
after MRM seems to result in no increase in postoperative complications, may
reduce  the incidence of flap necrosis.
Petrek et al45 in their study randomized 65 patients with carcinoma  to two
groups, single or multiple drains. For axillary dissection, randomization to multiple
drains meant placement of four catheters in the axilla, and randomized to the single
drain, one catheter in the axilla.  Multiple drains didn’t confer any added advantage
to single drain over amount & duration of fluid drainage.
Suction vs Passive drain
Traditionally, wound drainage was done using static drains, such as tube or
Penrose drains. However, since the development of continuous closed suction
17
drainage in 1947 by Murphy46, closed suction drainage has superseded static wound
drainage, as this increases freedom of movement, decreases need for bulky
dressings and the incidence of infection  is drastically reduced and  requires less
time for nursing care.
Nadkarni  et  al9 randomized 160 patients with breast malignancy , This
enabled them to know  the  effect of 2 different  factors use of scissors/electro
cautery and suction/corrugated drains on the occurence of postop seroma formation
. They concluded that the use of different  surgical methods or drainage has no
effect on the postop seroma formation.
Low pressure Suction vs High-pressure drain
The negative pressure on the suction drainage has been found to be
significantly influence postoperative drain output , a high negative suction drain
may disrupt  the severed lymph vessels from sealing off thus leading to prolonged
drainage leading to increased hospital stay.47
Wedderburn et al48 compared the use of low pressure and high pressure
drains in 69 patients following mastectomy and axillary clearance. The results
revealed no statistically significant difference between the two groups of patients
(P>0.05) in terms of daily drainage
Bonnema etal49  compared effect of negative pressure on fluid production
RCT in 141 patient. Not much difference noticed b/w the low  & the high vacuum
18
group  in volume  and duration 9.5  vs 10 days of seroma production,  There was a
positive correlation b/w BMI  and seroma.
Early Drain removal vs Late Drain removal
Many surgeons removed drain when it is  less than 20–50 mL in the
preceding 24 hr , which delayed their discharge, causes discomfort to the patient,
and increased the overall costs.16,21,51-55 This also delays starting on adjuvant
radiotherapy or chemotherapy and wound healing. Prolonged drainage may also
increase the hospital stay and the risk of infection by allowing retrograde migration
of bacteria.Indiscriminate or premature withdrawal of postoperative drains
irrespective of the amount of fluid drained may be accompanied by an increase in
the incidence of axillary seromas.51-54
Gupta et al16 randomized121 patients into five-day group (n=64) and eight-
day group (n=57). They concluded that 5-day post-operative drainage is as safe as
8-day post-operative drainage in the management of patients undergoing major
breast surgery, but results in an increase in seroma aspiration and aspiration volume
Parikh  et  al52randomized 100 patients having undergone (MRM) to either
drain removal at 3 or at 6 days post-operatively. More seroma occurred in the group
whose drain was left in situ longer.
Liu and McFadden53 studied 50 consecutive patients undergoing a standard
breast conservation surgery &  ALND for breast cancer. The axilla  drained with  7-
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Fr  suction drain. drains were removed  after POD 1 & prior to discharge from the
outpatient surgical center.No complications were seen in all  50 patients This
short-term method reduced the incidence & the  morbidity of  seroma
formation.
Baas-Vrancken Peeters et al54 conducted an RCT comparing twenty fourhr
to long-term drainage.  Mainly duration in hospital stayed was taken into account
and followed by seroma and its complications. Each group had 50 patients.In 24 h
drainage , short stay in hospital noted(2.5 vs., 4.6 , P < 0.001).  They observed that
24 h drainage following ALND is economical and free of wound complications
and seroma formation compared to long term drainage.
Dalberg et al30 studied the results from a multicentre randomized trial
which included 247 patients had undergone (MRM) five Swedish hospitals between
1993 and 1997. Of these 247 patients a total of 198 patients were supposed to have
the drain removed 24 h later or to keep the drain till < 40 ml / day discharge.
earlyremoval had more chances of seroma formation(48% vs. 20% P <
0.001)and a shorter stay in hospital(2.8 days vs. 4 days, P <0.001)
The evidence in established worksopined in favour of early drain removal
with less wound complications .
20
EXTERNAL COMPRESSION DRESSING
The use of pressure garment or compression dressings is to reduce the dead
space by giving an external force onto the flaps and to facilitate flap attachment to
underlying muscle, and thus reduces the  seroma formation.
Chaturvedi57used external compression and found lessseroma occurence.
He used 6” crepe bandages, which were applied circumferentially around the chest
wall,immediately after the operation with the opposite breast was included in it.
Chen  et  al15 in their study randomized 41 patients with breast cancer to
getpressure garment to be used after surgery or not. The garment was worn from
the 1st post-op day up to 14 days. They found no added advantage in post-op
drainage with the use of a pressure garment. More problems were seen with the
patients without pressure garments.seroma occurred in patients not using the
garment. The use of the pressure garment appeared to increase the duration of use
of the drain (6.8 vs. 6.1 days), these differences in the two groups was not
significant.
O’Hea et al58 in an RCT randomized 135 patients undergoing surgical
treatment for breast malignancy to receive a external compression or conventional
dressing. Dressing remained till postop day 4. Patients in the standard dressing
were done with a front-fastening Surgibra only. Drains were taken out when the
drainage was < 50 cc only. Duration of drains in both the groups were almost
similar. The external compression dressing did not give any additional
21
advantage to prevent seroma formation, frequent use of a compression in all
cases to reduce postoperative drainage afterALND for breast cancer is not
warranted.
Kontos et al59 compared 200 patients who had undergone MRM were given
external compression  on the skin flaps and the axilla immediately  (group A) with
a patients of no external dressing group (B). Drains were removed when drain
output< 30 ml per day, or on post op day 8. Mean time with drains kept in situ were
4.9 and 5.5 days in groups A and B. The differences seen were significant. They
concluded that these findings are supportive of pressure dressing as an effective
method to reduce seromaformation .
Unalp and Onal20, in their retrospective analysis of 119 patients observed
out of 101 patients who were given compression dressing postoperatively, 12
developed seroma whereas five patients developed seroma out of the 18 patients
who did not use compression dressing. The P value of 0.158 was not significant and
they concluded that compression dressing was not a factor that reduces seroma
formation
22
Figure3 : Application of Compression Bandage - Technique
Sterile gauze pads kept over the surgical wounds
Elastoplast bandages applied with pressure covering IpsilateralHemithorax in layers
23
Post application of Compression dressing
Table 5: Obliteration of dead space by external pressure
Authors
Type of
Study
Patients
(n)
Study Method P value
Chen et al,
199815
RCT 40
Pressure Garment (0)
Vs None (5%)
NS
O’Hea et
al,199958
RCT 135
CD Vs Normal
dressing
CD  > Normal
(P<0.01)
Unalp et
al,200720
Retrospect
ive
119
Pressure Garment
(12%) Vs None (28%)
NS
Kontos et
al, 200859
Comparati
ve
400
Pressure Garment
(2.5%) Vs None (16%)
Significant
NS = Not Significant    CD = Compression Dressing
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SUTURING OF SKIN FLAPS
Larsen  et  al61 used  subcutaneous suture  to fix the flaps to  the deep
muscles and fascia with 35 to 50 fine cotton sutures after (MRM) with  external
pressure  dressing.This procedure gave good cosmetic result and with less
morbidity and faster recoveryand drastically reduced seroma formationand drains
were removed earlier than other patients.
Chilsonet al31 used  a  flap  tacking  procedure  that  closes  the  axillary  fossa
dead space and tacks the mastectomy flaps to the chest wall. This study in (MRM)
demonstrated a significant decrease (25.4% vs. 38.6%, P = 0.038) in the incidence
of seroma when flap tacking was performed. They opined that the flap tacking
procedure reduced post mastectomy seromas, (P < 0.0001).
Schuijtvlot et al62 in a prospective audit 97 patients following breast-
conserving surgery for carcinoma with axillary dissection found that the use of an
additional buttress suture inserted between the axillary skin and the chest wall
decreased the occurrence of seroma  from 52% to 24% (P<0.007). The buttress
suture was a no. 1 size prolene suture was placed through the axillary skin, passed
into the Serratus Anterior muscle on the chest wall, thus obliterating the axillary
space.
In  the  RCT by Hamy et al63, axillary padding with FAL gave satisfactory
cosmesis, reduced seroma occurrence.(27% vs. 80%, P<0.001) in patients
undergoing BCS without axillary drainage.
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prospective study by Classe et al7,100 womenwere randomly allocated to two
groups, axillary padding without drain (n=47) or axillary suction drain (n=51).In
the axillary padding group, the length of hospital stay was significantly reduced
from 4.5(±2) days to 1.8(±1) days (P <0·001).
Coveney et al64 in RCT involving 39 patientsundergoing  (MRM)  were
randomized to undergo flap fixation to underlying muscle or conventional skin
closure. Drainage had reduced significantly than in skin closure patients (P < 0.05)
in the group with flaps fixed ,in flap sutured group few developed seromas, 5 (25%)
vs. 17 (85%), P < 0.001. They concluded that suturing skin flaps to underlying
muscle reduces local morbidity
In the RCT by Purushotham et al 17, 375 patients undergoing surgery for
breast malignancy were segregated to conventional surgery or suturing of flaps
with no drain. Patients segregated to control arm had 2 suction drains mastectomy
flap which were removed, once volume was<fifty ml/day or at post op day 5,
whichever occurred earlier. In the study arm, the flaps were fixed  to the underlying
PM muscle and Serratus anterior muscles with multiple   3 – 0 Vicryl sutures ,
starting  at the apex of the axilla and cephalic aspect of upper flap. Long thoracic
nerve was secured. No sutures were inserted in the cavity of the breast following
wide local excision. The results revealed a significant reduction in hospital stay.
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Figure 4: Dead space after Axillary dissection11
Figure 5: Suturing of dead space after mastectomy17
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POST OPERATIVE FACTORS
Shoulder Exercise
Shamley et al 23, in a study of delayed vs early postoperative exercise
following (MRM), showed that evidence from 12 RCTrecommend the use of
delayed  exercise  (P = 0.00001) to reduce seroma formation.Delayed  shoulder
exercise is  much more better thanimmediate postoperative exercise at reducing
seroma and there is no evidence that it wil derange shoulder movements .
Drain Output
Barwell et al51 compared 63 patients after BCS (n = 37) or MRM (n=26).
Suctiondrains were removed  after a median of 4 days . In all, 32 patients (51%)
later developed seroma requiring needle aspiration.Seroma formation was
associated with a larger total suction drain volume. The median yield of axillary
lymph nodes was significantly greater in those who developed seromas (11 vs. 8;
P< 0.002). There was not much change in the volume drained 24 h preceding drain
removal (mean 60 ml vs. 50 ml). Thus, they observed that longer in situ drains was
not much useful to prevent seroma formation.
Kopelman et al47in a RCT trial defined the correct time to remove the drain
after MRM  90 patients. 42 were randomized to have the drain removed on
postoperative day 3, and the rest to keep it till <35 ml/24 hours.  Main outcome
measure ere the formation of seroma, wound infections, need to reinsert the drain,
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and duration of hospital stay. Earlier the drain removed, carried a risk of seroma
formation (9/42 compared with 2/48, p = 0.02) unless the total amount of fluid
drained during the first 3 postop days was less than 250 ml.
Unalp and Onal20 from their retrospective analysis of 119 patients conclude
that later removal of drains didn’t increase seroma  occurence  rate.  They observed
that  a  drain  volume  >  50  mL? day   for  2  days   following  surgery  affected
seromadevelopment. They,recommend drainage to be continued till  flow rate at 48
hours is seen and daily drainage is lower than acceptable limit (up to 25 mL? days).
Loo and Chow12 in their retrospective analysis of 119 patients identified
drain output exceeding 500 ml in first three postoperative days and drainage more
than eight days as significant risk factors for seroma formation. Lumachi et al19
observed that total drainage is a predictor for seroma formation.
ADJUVANT THERAPY
Seroma can delay the initiation of adjuvanttherapy in patients after
MRM.However, adjuvant chemotherapy and radiotherapy can contribute to seroma
formation. Sultan and Madhere65reported a case of seroma formation 4 years after
breast reconstructive procedure and while on docetaxel . They did not establish a
definite causal relationship between seroma formation and docetaxel.
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NON-SURGICAL MODALITIES
Due to the associated complications and time constraints associated with the
surgical management, Fibrin glue was used which interacted with the damaged
tissues  andfavouring the fibroblasts growth and in wound healing . It favors
haemostasis by preventing hematomas, which delay the surgical healing processes,
blocks the lymphatic channels and thus  reducingseroma formation;  closes the dead
spaces through tissue adhesion.
Table 6: Recent randomized trials using tissue sealants
Author
Total
Patients
Sclerosant
used
Seroma
with / without
sealant (%)
P value
Ulusoy et al,
200368
54 Fibrin glue 18/11 NS
Jain et al, 200418 58 Fibrin glue 34/41 0.01
Mustenan et al,
200469
40
Fibrin glue +
aproptinin
20/26 NS
Johnson et al,
200570
82 Fibrin glue 37/45 NS
Ruggiero et al,
200871
50
Fibrin glue +
collagen
11/16 0.02
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Bonnema et al25 noted that seroma contained less amount of fibrinogen.
Thus use of fibrin glue with its clot forming properties reduced seroma formation.
NS = Not Significant
Jain et al18 showed that there was a positive correlation with the use of
fibrin sealant on seroma occurence,consequent use of drains led to clot disruption
and not adding to much advantage .
Johnson et al70 found no reduction in seroma formation and concluded that
the  fibrin glue was not cost effective , technique involved in its application is
difficult  indicated that it has no added  advantage over normal suction drains
Ruggiero et al71conducted an RCT randomized 50 patients who underwent
MRM. Fibrin glue spray and a collagen patch were applied to the axillary fossa in
half of the patients, the other half were treated conventionally. Suction drainage
was removed b/w post op days 3 & 4. Seroma amount and duration were
significantly reduced and seroma aspiration and multiple hospital visits drastically
reduced .
Mustenan et al75,studied the use of fibrin glue & fibrinolysis inhibitor, he
demonstrated that there was not much effect on seroma formation.
Still further randomized control studies are needed to effectively point out
the causative factors for seroma formation and it is difficult toidentify patients who
will suffer from seroma.
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AIMS AND OBJECTIVES
? To establish an association between various risk factors of seroma
formation.
? To know whether the risk factors act independently or by synergism
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SURGICAL ANATOMY
Gross  Anatomy
Breast is situated in superficial fascia of anterior thoracic wall .it consists of
15 to 20 lobes wit fibrous tissue and adipose tissues. Deep layer of superficial
fascia covers the posterior aspect of breast, the retromammary  bursa is situated
between deep layer of superficial fascia and clavipectoral fascia .4
Axilla
Pyramidal shaped between the upper extremity and thoracic wall .it consists
of 4 walls, an apex ,& a base . Base is made up of axillary fascia and skin . Apex is
an aperture and extends into neck through cervicoaxillary canal. The anterior wall
is made up of pectoralis major(PM) and minor muscle(Pm) .posterior wall is made
up of subscapularis muscle , lateral wall is made up of humerus , medial wall is
made up of serratus anterior muscle .
Breast is located just deep to dermis, suspensory ligaments of cooper pass
from the septa that divides the breast into multiple lobules .
components of the brachial plexus, and axillary LN  groups  are seen. On the
left side, the breast is cut to expose its structure in saggital view.
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Figure 6: The contents of the axilla, axillary artery & vein
BLOOD SUPPLY
Breast is supplied by
1. Branches of  internal mammary  artery
2. Branches of posterior intercostal arteries
3. axillary , lateral thoracic , &thoracoacromial artery .
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Venous Drainage
1. Drain into internal thoracic vein
2. Tributaries of axillary vein
3. Perforating branches of posterior intercostal veins
Bastons plexus of veins provide a route for metastatic emboli to reach the
vertebral bodies , ribs  and CNS
Figure 7: Diagrammatic Presentation of blood supply to breast
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LYMPHATIC DRAINAGE OF THE BREAST
1. The  lateral group, made up of 4 to 6  LN  that lie near  to axillary vein
2. The anterior group consists of 4 or 5LN  major portion of the drainage of
lymph from breast is to this group . Lymph drains primarily from these
lymph nodes into the central LN
3. The  posterior group, made up of  6 to 7 LN  that lie along thesubscapular
vessels.
4. The central group made up of  3 to 4   lymph nodes that are present in the
axilary pad of fat  usually behind  to the pectoralis  muscle.Lymph from
thecentral nodes passes directly to the subclavicular (apical) nodes.
5. The  apical group, made up of   6 to 12 LN located partly  posterior to the
upper border of the Pm  and partly superior to it. They mayReceive lymph
directly or indirectly from all the other groups of axillary lymph nodes.
 6. The   Rotter‘s group, consists of 1 to 4 small LN that are located Betweenthe
PM and minor muscles in association with the pectoral branches of
thethoracoacromial vessels.
Internal mammary group is situated in retrosternalspaces, the right internal
mammary group drains into right lymphatic duct, and the left enters the main
thoracic duct.Cross communication between lymphatics from each breast,explains
the metastatic involvement of opposite breast and axilla.
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Sub areolar plexus plays no important in lymphatic drainage of breast.
Figure 8: diagrammatic representation of lymphatic supply of breast.
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Figure 9: Level I lymph nodes include the anterior, lateral &scapular groups;
level II, the central group; and level III, the apical. There are three levels or groups
of lymph nodes that are defined by their location relative to the pectoralis minor.
The direction indicates the general direction of lymph flow. The axillary vein and
its major tributaries associated with the pectoralis minor are included
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CLASSIFICATION OF BREAST TUMORS
Table 7: Histological Classification of Breast Tumors
1 EPITHELIAL TUMOURS
A. Benign
1. Intraductal papilloma
2. Adenoma of the nipple
3. Adenoma
a. Tubular
b. Lactating
a. Malignant
b. Non invasive
c. DCIS
d. LCIS
2. Invasive
a. Invasive ductal carcinoma(IDC)
b. IDC  with predominant intraductal component
c. Invasive lobular carcinoma
d. Mucinous carcinoma
e. Medullary carcinoma
f. Papillary carcinoma
g. Tubular carcinoma
h. Adenoid cystic carcinoma
i. Secretory carcinoma
j. Apocrine
k. Carcinoma wit metaplasia
3. Squamous type
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4. Spindle cell type
5. Cartilaginous and osseous type
a. Mixed type
b. Others
II Mixed connective tissue and Epithelial tumors
a. Fibroadenoma
b. Phyllodes tumour
c. Carcinosarcoma
III. Miscellaneous tumours
a. Soft  tissue tumours
b. Skin tumours
c. Tumours of haematopoietic and lymphoid tissues
IV. Unclassified tumours
STAGING OF BREAST CANCER
TNM staging system requires microscopic confirmation and histological
typing of the tumour before attempting any stage classification.
Table 8: AJCC/TNM Clinical Staging System
TUMOUR(T)
Tx Primary tumour cannot be assessed
T0 No evidence of primary tumour
Tis Carcinoma in situ
Tis (DCIS) DCIS
Tis(LCIS) LCIS
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Tis pagets
disease
Pagets disease of the nipple with no tumour
T1 Tumours <2cm in greatest dimension
T2 Tumour  >  2cm  and  not  more  than  5  cm  in  greatest
dimension
T3 Tumour > 5cm in greatest dimension
T4
T4a
T4b
T4c
T4d
Tumour of any size with direct extension t
To (a) chest wall  (b) only as described below
Extension to chest wall , not including pectoralis muscle
Oedema or ulceration of the skin of the breast or satellite
nodules confined to the same breast
Both T4a and T4b
Inflammatory carcinoma
REGIONAL LYMPH NODES
Nx Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Metastasis to movable axillary lymph node
N2
N2a
N2b
Metastasis in ipsilateral axillary lymph nodes fixed or
matted or clinically apparent ipsilateral internal mammary
nodes in the absence of clinically evident axillary lymph
node metastasis
Metastasis to ipsilateral axillary lymph nodes fixed to one
another or to other structure
Metastasis only in clinically apparent ipsilateral internal
mammary nodes and in  the absence of clinically evident
axillary lymph node metastasis
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N3
N3a
N3b
N3c
Metastasis in ipsilateral infraclavicular lymph nodes or
clinically apparent ipsilateral internal mammary nodes and
in the presence of clinically evident axillary lymph nodes
metastasis or metastasis in ipsilateral supraclavicular
lymph nodes with or without axillary or internal mammary
lymph nodes involvement
Metastasis in ipsilateral infraclavicular lymph nodes and
axillary lymph nodes
Metastasis in ipsilateral internal mammary nodes and
axillary lymph nodes
Metastasis in ipsilateral supraclavicular lymph nodes
Mx Distant metastasis cannot be assessed
M0 No distant metastasis
M1 Distant metastasis
Table 9: Staging of Breast Cancer
Stage 0 Tis N0M0
Stage1 T1 N0M0
Stage IIA T0 N1 M0
T1 N1 M0
T2 N0 M0
Stage II B T2 N1 M0
T3 N0 M0
Stage III A T0 N2 M0
T1 N2 M0
T2 N2 M0
T3 N1 M0
T3 N2 M0
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Stage III B T4 N0 M0
T4 N1 M0
T4 N2 M0
Stage III C Any T N3 M0
Stage IV Any T Any N M1
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MATERIALS AND METHODS
Study design : Prospective study
Study Place : Department of General Surgery
Kilpauk medical college and Government Royapettah
Hospital
Duration of Study : Jan 2013 to October 2013
Number of patients: Fifty Patients
Ethical committee clearance obtained
Written informed consent obtained
Inclusion criteria
? All cases of breast cancer undergoing Modified Radical
Mastectomy.
Exclusion criteria
? Cases of Mastectomy and Axillary dissection for
indications other than carcinoma.
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? Cases undergoing palliative mastectomies and
incomplete axillary dissection.
? Cases of breast cancer surgery in males
? Previous surgical procedures in and around the axilla
? Bilateral breast cancer
? Simultaneous reconstructive surgery
? Other serious underlying medical illness(es) precluding
full study participation
OPERATIVE TECHNIQUE
All patients underwent a complete clinical examination and relevant
investigations required for diagnosis and staging.  All participating women were
informed about their diagnosis, the surgery to be performed and about the study
before the surgery.
The surgery was performed under general anesthesia with patient supine on
the operating table with both arms abducted. A third generation cephalosporin
Cefotaxime was used as perioperative antibiotic and perioperative analgesics were
used as per standard protocol. The operated side was painted and draped as per
protocol. The operative technique was same throughout the study periodin patients
undergoing mastectomy, a horizontal elliptical incision was used which included
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the tumor with at least 2 cm skin margin. The flaps were raised using electrocautery
medially up to mid sternum, superiorly up to the clavicle and inferiorly 2 cm below
the infra mammary crease. Skin was closed with ethilon.
Axillary node dissection consisted of an en bloc removal of level I& II
lymph nodes. Flaps were raised using electrocautery. The axillary contents were
cleared from the the axillary vein extending from the chest wall to the anterior
border of latissimus dorsi muscle posteriorly &  anteriorly  lateral border of PM
muscle. The inferiorly extended up to 5th intercostal space. The ipsilateral arm was
then flexed, the PM and Pm muscles were retracted, and elevated and axillary
contents dissected to the apex of the axillary cavity. Care was taken to preserve the
nerve to Serratus anterior and thoracodorsal nerves and vessels. A 14 to 16 Fr
closed suction drain was placed in the axilla. The wounds were dressed with sterile
gauze pads.
Definitions
1. A  seroma  is  defined  as  any  palpable  fluid  collection  in  the  axilla.  Any
seroma aspirated once a week or earlier if required and a sample sent for
culture and sensitivity.
2. Wound infection was defined as erythema, cellulitis, purulent drainage,
wound gaping, skin necrosis, or positive microbiology at the incision site
that needed antibiotics.
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All patients were followed up in the outpatient clinics. Data was collected and
recorded longitudinally.output, cumulative postoperative day 7 drain output, total
drain output, duration of drainage,
Outcome Measures
The primary endpoint of the study was the incidence of seroma formation.
The other parameters that were measured were postoperative day 1 drain output,
cumulative postoperative day three drain ,  Operative details like;  use of electro-
cautery, suction drains ,axillary padding were also noted, implementation of upper
limb (on the side operated) physiotherapy were noted.  Histopathological reporting,
the number of lymph nodesremoved & wound complications. Analysis of risk
factors for seroma formation was also done.Seroma was managed by regular
aspirations under aseptic precautions and the drain removal was delayed until the
resolution of seroma.
METHOD OF STATISTICAL ANALYSIS
Descriptive statistical analysis has been carried out in the present study.
Results on continuous measurements are presented on Mean ? SD  and  results  on
categorical measurements are presented in percentage. (%). Chi-square test has
been used to find the significance of study parameters on categorical scale between
two groups. Student ‘t’ test has been used to determine the significance between
two group means. All analyses were two tailed and p <0.05 was considered
significant. SPSS version 16.0 was used for data analysis.
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Graph 10:Distribution of seroma in study
population (N=50)
RESULTS
DEMOGRAPHIC DATA
50 consecutively admitted female patients with the diagnosis of carcinoma
breast counseled for MRM were included in the study. SIXTEEN out of 50
patients, accounting for 32 percent, developed seroma
Seroma Frequency Percentage
Yes 16 32.0
No 34 68.0
Total 50 100.0
TABLE 10:Distribution of seroma in study population
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GRAPH 11: DISTRIBUTION OF SIDE OF
TUMOUR IN STUDY POPULATION
Right Left
RIGHT
LEFT
TABLE 11:Distribution Of  Tumour  Side In Study Population
Seroma
Total
‘p’value
0.805
Yes No
side Right Count 6 10 16
% within side 37.5% 62.5% 100.0%
Left Count 10 24 34
% within side 29.4% 70.6% 100.0%
Total Count 16 34 50
% within side 32.0% 68.0% 100.0%
6 among the seroma group were found to be right sided tumors accounting
for 37.5%,ten among the seroma were found to be left sided tumors (29.4%).P
value was insignificant 0.80
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56.0
GRAPH 12:  DISTRIBUTION OF HYPERTENSION
IN STUDY POPULATION
Yes No
44.0
TABLE 12: Distribution of Hypertension In Study Population
Seroma
Total
‘p’ value
0.001
HTN Yes No
Yes Count 15 7 22
% within htn 68.2% 31.8% 100.0%
No Count 1 27 28
% within htn 3.6% 96.4% 100.0%
Total Count 16 34 50
% within htn 32.0% 68.0% 100.0%
15 among the seroma group were found to be hypertensive accounting for
68.2%;seven among the non-seroma group were hypertensive, 32.1%.P value was
significant 0.001
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GRAPH 13: DISTRIBUTION OF NEO
ADJUVANT CHEMOTHERAPY IN STUDY
POPULATION
Yes No
YES
NO
TABLE 13: Distribution of Neoadjuvant chemotherapy in study population
Seroma
Yes                         No
Total ‘p’value
NAC  YES 7 10 17
NO 9 24 33 0.498
TOTAL 16 34 50
7 patients who had received neo adjuvant chemotherapy developed seroma,
and 9 patients who received no neoadjuvant chemotherapy developed seroma.  P
value was 0.498, statistically insignificant
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GRAPH 14: DISTRIBUTION OF
PREOPERATIVE RADIOTHERAPY
IN STUDY POPULATION
Yes No
TABLE 14: DISTRIBUTION OF PREOPERATIVE
RADIOTHERAPY IN STUDY POPULATION
seroma
Total
‘p’value
1.00
Yes No
pre_op_r Yes Count 1 2 3
% within
pre_op_r
33.3% 66.7% 100.0%
No Count 15 32 47
% within
pre_op_r
31.9% 68.1% 100.0%
Total Count 16 34 50
% within
pre_op_r
32.0% 68.0% 100.0%
Out of 3 patients, who received preop radiotherapy only 1 developed
seroma,15 patients who had not received radiotherapy developed seroma.  P value
was 1.000, statistically insignificant
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GRAPH 15: DISTRIBUTION OF
MEAN TUMOUR SIZE (CM) IN
STUDY POPULATION
TABLE 15:DISTRIBUTION OF MEAN TUMOUR
SIZE IN STUDY POPULATION
Seroma N Mean SD Min Max ‘p’value
Yes
No
16
34
5.31
4.70
2.41
2.35
3.00
2.00
10.00
12.00
0.403
Total 50 4.90 2.36 2.0 12.00
The mean tumour size of patients who developed seroma was
5.31+2.41(3.0-10.0),  whereas  the  mean  tumour  size  of  those  without  seroma  was
4.70+2.35 (2.0-12.0) cm.
P value was 0.403, statistically insignificant.
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GRAPH 16: DISTRIBUTION OF MEAN AGE
(IN YEARS) IN STUDY POPULATION
Yes No
55.1
48.4
TABLE 16: DISTRIBUTION OF MEAN AGE
IN THE STUDY POPULATION
Seroma N Mean age in yrs SD Min Max ‘p’value
Yes
No
16
34
55.06
48.05
6.56
11.29
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26
69
75
0.56
Total 50 50.52 10.44 26 75
The mean age of patients who developed seroma was 55.06+6.56(46-69),
whereas the mean age of those without seroma was 48.05+11.29 (26 – 75) years.P
value was 0.560, statistically insignificant.
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GRAPH 17:DISTRIBUTION OF MEAN
BMI
 ( kg/m²)  IN STUDY POPULATION
TABLE 17: Distribution ofMean BMI (kg/m2) in the study population
Seroma N Mean age in yrs SD Min Max ‘p’value
yes
No
16
34
26.16
22.64
1.79
2.62
21.30
18.04
28.40
29.01
0.001
Total 50 23.76 2.89 18.04 29.01
The mean BMI of those with seroma was 26.16+1.79 (21.30-28.40); the
BMI for patients without seroma was 22.64+2.62 (18.04-29.01) kg/m2.
P value was highly significant 0.001
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GRAPH 18: DISTRIBUTION OF DRAIN OUT PUT ON POD
1 IN STUDY POPULATION
M
L
TABLE 18: Mean drain output on POD 1 in study population
Seroma N Mean SD Min Max ‘p’value
Yes
No
16
34
200.31
147.94
36.44
29.31
120
100
275
200 0.032
Total 50 164.70 39.92 100 275
The mean drain output on day 1 in seroma group was 200.31+36.44 (120-
275) and in no seroma group was 147.94+29.31 (100-200) milliliters (ml),
P value is 0.032, statistically significant.
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GRAPH 19: DISTRIBUTION OF MEAN DRAIN OUT
PUT ON  POD2 IN STUDY POPULATION
M
L
TABLE 19: Mean drain output on POD2 in study population
Seroma N Mean SD Min Max ‘p’value
Yes
No
16
34
190.00
127.35
23.66
35.188
170
70
250
200 0.043
Total 50 147.40 43.32 70 250
The mean drain output on day 2 in seroma group was 190.00+23.66 (170-
250) and in no seroma group was 127.35+35.18 (70-200) milliliters (ml),
P value is 0.043, statistically significant.
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GRAPH 20: DISTRIBUTION OF MEAN DRAIN
OUTPUT ON POD 3 IN STUDY POPULATION
M
L
TABLE 20: Mean drain output on POD 3 in the study population
Seroma N Mean SD Min Max ‘p’value
Yes
No
16
34
186.25
111.47
20.28
35.43
150
60
220
200 0.021
Total 50 135.40 47.04 60 200
The mean drain output on day 3 in seroma group was 186.25+20.28 (150-
220) and  in noseroma group was 111.47+35.43 (60-200) milliliters (ml),
 P value is 0.021, statistically significant.
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GRAPH 21: DISTRIBUTION OF MEAN TOTAL
DRAIN  OUTPUT IN STUDY POPULATION
ML
TABLE 21: Mean total drain output in the study population
Seroma N Mean SD Min Max ‘p’value
Yes
No
16
34
800.60
500.45
70.88
100.67
750.00
300.00
1050.00
920.00 0.011
Total 50 600.46 200.70 300.00 1050.00
The mean total drain output in seroma group was 800.60+70.88 (750-1050) and   in
no seroma group was 500.45-100.67 (300-920) milliliters (ml),
P value is 0.011, statistically significant.
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GRAPH 22: DISTRIBUTION OF MEAN DRAIN
REMOVAL DAY  IN STUDY POPULATION
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TABLE 22: Mean drain removal day in study population
Seroma N Mean SD Min Max ‘p’value
Yes
No
16
34
15.50
9.41
1.82
2.32
13.00
7.00
19.00
16.00 0.036
Total 50 11.36 3.59 7.00 16.00
The mean drain removal day in seroma group was 15.50+1.82 (13-19) and in no
seroma group was 9.41+2.32 (7-16)
P value is 0.036, statistically significant.
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GRAPH 23: DISTRIBUTION OF MEAN NUMBER OF
LYMPH NODES REMOVED  IN STUDY POPULATION
TABLE 23: Mean number of lymph nodes removed in the study population
Seroma N Mean SD MIN MAX ‘p’value
Lymph          Yes
No
16
34
17.34
15.91
7.14
4.98
8 40 0.497
The mean number of lymph nodes removed in the seroma group was 17.34+7.14
(8-40), whereas in no seroma group was 15.91+4.98 (10 – 56).
P value was insignificant 0.497
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DISCUSSION
Breast cancer is the most common cancer in women and surgical
management remains the main line of management. The most common types of
breast surgeries are MRM and BCS. Seroma is the commonest sequel following
breast cancer surgery. Seroma accumulation elevates the flaps from the chest wall
and axilla thereby hampers their adherence to the tissue bed. Although it usually
resolves within a few weeks, excessive fluid accumulation will stretch the skin and
cause it to sag, resulting in patient discomfort and prolongation of the hospital stay.
It can thus lead to significant morbidity such as wound hematoma, wound
infection, flap necrosis, wound break down, prolonged hospitalization,
psychological distress, delayed recovery, & delay in starting chemotherapy.22
Thus, although a number of factors have been correlated with seroma
formation, strong data on factors associated with seroma formation are still rare,
and it is difficult to identify patients who will ultimately suffer from seroma.
Various studies have shown that s that suturing of skin flaps is a successful means
of reducing seroma formation.7, 17, 60-64 The success of external compression
dressings have not yet been validated adequately through randomized studies.15,58,59
Early drain removal has also been shown not to significantly affect seroma
formation while reducing duration of drainage and other postoperative morbidity.
Complications due to these methods are not much different from the standard drain
method and are not frequent or serious.
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Our study included 50 randomly selected patients with the diagnosis of
Carcinoma  breast  undergoing modified radical mastectomy. In our study, 32 %of
patients  developed seroma. E. Hashemi et al in their study on 158 patients with
breast cancer undergoing either modified radical mastectomy or breast
preservation,  overall  seroma rate  was  35%. Gonzalez  E.  A.  et  al  in  their  study on
359 patients undergoing either modified radical mastectomy or wide local  excision
and axillary lymph node dissection showed overall seroma rate of 15.8%, 19.9% in
modified radical mastectomy group and 9.2% in breast-conserving group. Seroma
rate in a study by Unalp H. R. et al was 14.28%.
The mean age of presentation was 55.06 years (6.57), p value was 0.506 no
significant association was established between age of the patient and seroma
formation. Menton M. et al opine that seroma formation increases with increasing
age of the patient. On the contrary, K. Kuroi et al quoted that existing  evidence
was inconclusive for age with respect to seroma formation, as did E. Hashemi et al.
The  mean  age  in  E.  Hashemi  et  al  study  was  46.3  years  (SD+11.9).  Unalp  et  al
reported a mean age of 53.13 years (SD+13.26), which is comparable to the mean
age of patients in studies from India like Nadkarni et al9 and Chintamani et al.50
The mean age is lower than patients in studies from other parts of the world like
Gupta et al16, Purushottam et al 17,32, Jain et al18, Lumachi et al 19, Galatius et al42,
O’Hea et al59 and Ruggerio et al.73. This underlines the fact that breast cancer
occurs at an earlier age in India than in the western countries.
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Mean BMI was 26.16 kg/mm2(SD+ 1.79).In our  study BMI of patients
fromNoseroma group had a lower BMI (22.64), the difference was statistically
significant.Our study opines that there is association between BMI and seroma
formation.
Among the seroma group ,15 of 16 patients (68%), were hypertensive, while
in non seroma group , 7 of 34  patients were known hypertensives. There was
significant association between seroma formation and history of arterial
hypertension in  the patient. Literature shows that high BMI and arterial
hypertension are considered risk factors , Douay et al, Kumar et al29 found a
significant association b/w BW and HTN with seroma.
In the study, 7 of the seroma group patients received neoadjuvant
Chemotherapy,Whereas 9 patients who had not received neoadjuvant
chemotherapy developed seroma significant reduction in seroma rate could notbe
demonstrated from the study as similarly concluded by Unalp H. R. et al. The mean
drain output during first 24 hours in seroma group was 200.31 (SD+36.4), that in
no seroma group was 147.94ml (+29.31), there was significant difference between
both the groups, p value was 0.032. in the following 24 hours seroma group had
190.0ml(SD+23.66) and in no seroma group was 127.35ml(SD+35.18), the
observed difference between both the groups was  Statistically significant p value
was0.043 the drain output on post op Day 3 was 186.25 (SD+120.25) in seroma
group and 111.47 ml (SD+35.43) in no seroma group.the difference was statistical
significance, suggesting the probability of seroma formation in those patients with
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higher drain output on post op Day 3.k.kuroi et al , suggested that a positive
association between drainage volume during the initial 72 hrs and seroma
formation was consistent.
The mean number of lymph nodes removed in  seroma group was
17.34(SD+7.1)and no seroma group was 15.91(SD+4.98). the difference was
not statistically significant p value was 0.498
The mean drain removal day in seroma group was 15.5(sd+1.82) and in no
seroma  group was 9.41 (SD+4.98). the difference was not statically significant.
Although k.kuroi et al showed that seroma formation rate was significantly high in
patients following drain removal on post op day 5 when compared to drain removal
on post op day 8 . in our study , patients with seroma  had drain removed on days
ranging from (13-19) and in non seroma group
(6-17).
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CONCLUSION
The factors influencing seroma formation following modified radical
mastectomy for carcinoma breast are as follows;
HYPERTENSION has  significant association for seroma formation
Higher Body mass index has strong association for seroma formation
Higher drain output on post-operative day 1, pod 2,and pod 3 is likely to
predict the increased possibility of seroma formation.
Delayed removal of drain showed increased seroma formation
Factors like age of the patient, neo-adjuvant chemotherapy, number of
lymph nodes removed have no bearing on seroma rate.
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ANNEXURE
PROFORMA
Name  : Age :  Adm. No.:
Study No.: D.O.A.: D.O.Sx:            D.O.D.:
Presenting History
Duration and side of swelling/lump:
Past and Personal history
Co morbid illness : a.  diabetes mellitus
b. hypertension
Past Surgical/drug history
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Prior Therapy
1. Chemotherapy 2. Radiotherapy
General examination
Height (cm): Weight (kg):       BMI : Pulse: BP:
Local examination
Lump (SIZE, skin and nipple areola)
Lymph Nodes (Location, number & fixity)
1. Axillary
2. Internal mammary/ Supra clavicular/Infra clavicular::
Hb% (g/dL):
Course and Events in Hospital
Surgery Performed
Electro Cautery Used
Use of suction drain
Axillary padding
Upper Limb Exercise
78
Number of Lymph Nodes Removed:
Drain output:
POD 1  2 3 4 5 6 7 8 9 10
Drain output
(ml)
POD 11 12 13 14 15 16 17 18 19 20
Drain output
(ml)
POD 21 22 23 24 25 26 27 28 29 30
Drain output
(ml)
Date of drain removal: Total duration of drainage (days):
Total volume of drainage (mL):
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KEY TO MASTER CHART
Sl No Serial number
R RIGHT
L LEFT
Y YES
NAC NEO ADJUVANT CHEMOTHERAPY
BMI BODY MASS INDEX
PRE OP RT PREOPERATIVE  RADIOTHERAPY
MRM MODIFIED RADICAL MASTECTOMY
POD POSTOPERATIVE DAY
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Figure24 : specimen of breast and axillary pad of fat after MRM
82
Figure 25 : axillary vein and thoracodorsal trunk seen
after axillary lymph node dissection
83
Figure 26:  exposed pectoralis major muscle after MRM
84
Figure 27 : flap necrosis after MRM
85
Figure 27: post mastectomy seroma collection in left breast
SL NO Name Age Ip no
 Duration
of
 symtoms Side HTN DM
tumour
(cm)
size Height Weight BMI NAC
pre op
rt HB Surgery
lymph
node
removed
ELECTRO
CAUTER
Y
POD1
DO
POD2
DO
POD3
DO TOTAL DO
UPPER
LYMB
PHYSIO
THERPHY
DRAIN
REMOVAL
DAY SEROMA
1 banumathy 56 811 18 R Y Y 6 1.52 56.4 24.41 y n 9.6 mrm 22 y 200 170 170 820 y 14 y
2 kala 42 951 7 L NIL NIL 7 1.58 48.9 19.59 Y N 12.6 mrm 20 Y 160 110 100 625 Y 9 N
3 thulasi 48 1273 8 L NIL NIL 6 1.51 52 22.69 Y N mrm 18 Y 130 110 90 350 Y 10 N
4 rajeshwari 53 1652 10 R Y Y 9 1.47 57 26.38 Y N 8.6 mrm 10 Y 170 180 180 750 Y 13 Y
5 kamala 62 1671 11 L NIL NIL 8 1.61 59.6 22.92 Y Y 7.8 mrm 16 Y 160 150 160 600 Y 8 N
6 jagadeshwari 30 2876 2 L NIL NIL 2 1.5 52 20.78 N N 13.1 mrm 18 Y 200 180 160 860 Y 16 N
7 kurshid begum 75 2885 6 L NIL NIL 3 1.51 52 22.69 N N 9.4 mrm 16 Y 110 100 110 400 Y 9 N
8 gunamani 70 3357 5 L Y NIL 4 1.5 49.2 21.8 N N 8.8 mrm 15 Y 120 90 80 350 Y 8 N
9 vanaja 46 4062 6 R Y NIL 3 1.56 75 27.89 N N 9.9 mrm 40 Y 230 200 190 875 Y 13 Y
10 sudha 26 5552 1 R NIL NIL 4 1.5 55 22.1 N N 49.2 mrm 19 Y 130 110 90 350 Y 8 N
11 susheela 52 6873 7 L Y NIL 4 1.59 59.6 24.96 N N 7.6 mrm 15 Y 220 190 180 810 Y 16 Y
12 saroja 44 7359 4 L NIL NIL 5 1.62 57 21.99 N N 10 mrm 18 Y 130 100 100 375 Y 8 N
13 durusila 54 13588 8 L Y Y 4 1.63 71 26.72 N N 9.4 mrm 21 Y 275 250 220 810 Y 19 Y
14 rajeshwari 63 8044 13 R NIL NIL 6 1.52 68 22.74 Y N 9.2 mrm 19 Y 200 190 200 920 Y 15 N
15 sairabee 65 9429 17 L Y NIL 9 1.59 68.6 27.16 Y Y 8.9 mrm 24 Y 190 190 170 810 Y 18 Y
16 panjalai 44 3406 7 L NIL NIL 3 1.6 64 24.32 N N 13.8 mrm 13 Y 130 120 130 450 Y 8 N
17 sarojadevi 60 9147 6 L NIL NIL 4 1.59 68.4 27.14 N N 10.2 mrm 15 Y 170 140 100 525 Y 9 N
18 karpagani 48 9654 5 L Y NIL 3 1.54 59.6 23.58 N N 11 mrm 16 Y 160 150 130 610 Y 9 N
19 saraswathy 66 1032 4 L NIL NIL 4 1.49 56.7 25.54 N N 9.2 mrm 20 Y 180 190 170 775 Y 14 Y
20 thulasi 55 1124 7 L Y NIL 3 1.59 68.6 27.14 N N 9.9 mrm 18 Y 220 190 160 930 Y 14 Y
21 sahayarani 40 1204 3 R NIL NIL 4 1.6 58.9 22.72 N N 12.6 mrm 15 Y 120 90 90 300 Y 8 N
22 dilshad 60 1195 8 L NIL NIL 6 1.46 54 20.58 Y N 8.9 mrm 17 Y 170 120 90 570 Y 10 N
23 lakshmi 54 1302 5 L Y Y 4 1.5 70 27.6 N N 11.2 mrm 10 Y 210 190 190 875 Y 16 Y
24 shanthi 45 1288 7 R NIL NIL 5 1.58 61 22.68 N N 13 mrm 16 Y 150 130 90 375 Y 8 N
25 sundari 40 1431 6 L Y NIL 4 1.54 49.4 20.83 N N 12 mrm 19 Y 180 170 180 790 Y 14 N
26 padmavathy 48 394 6 L Y NIL 5 1.6 68.6 26.47 Y N 9.8 mrm 22 Y 190 170 210 960 Y 18 Y
27 sumathy 40 4307 4 L NIL NIL 3 1.59 59.4 22.92 N N 10.6 mrm 18 Y 200 150 140 535 Y 9 N
28 thasilim 30 6970 2 L NIL NIL 2 1.52 52 22.67 N N 14.6 mrm 14 Y 180 140 130 600 Y 11 N
29 kungumayee 50 8057 8 R NIL NIL 4 1.5 52 23.11 Y N 10.2 mrm 11 Y 160 200 130 650 Y 10 N
30 poumali 55 7001 10 R Y Y 3 1.5 57.9 25.06 N N 9.6 mrm 10 Y 120 190 220 890 Y 16 Y
31 ponnammal 55 9917 9 R NIL NIL 5 1.53 73.5 29.04 N N 8.8 mrm 14 Y 180 140 110 635 Y 11 N
32 rajalakshmi 56 1017 14 L Y NIL 9 1.54 62 26.14 Y Y 11.6 mrm 26 Y 140 100 120 675 Y 8 N
33 valasal 69 1177 8.5 L Y Y 4 1.47 66 21.3 N N 10 mrm 9 Y 260 240 200 880 Y 17 Y
34 ragini 60 1226 6 L NIL NIL 11 1.51 60 19.3 Y N 9.8 mrm 16 Y 110 80 70 530 Y 8 N
35 gandhimathi 40 3178 7 R NIL NIL 4 1.54 62 24.14 N N 15.2 mrm 13 Y 120 70 60 500 Y 8 N
36 sundari 47 3170 4 L Y NIL 3 1.56 48 19.63 N N 10.2 mrm 14 Y 110 100 70 450 Y 8 N
37 latha 41 6806 3 L NIL NIL 5 1.49 49 18.63 N N 9.8 mrm 19 Y 130 80 70 400 Y 8 N
38 chinnaponnu 60 5677 11 L Y NIL 12 1.51 64.6 28.33 Y N 11.2 mrm 29 Y 120 200 180 880 Y 14 N
39 achammal 50 9773 10 R Y Y 10 1.5 64.4 28.26 Y N 10.2 mrm 20 Y 190 170 180 830 Y 14 Y
40 shanthi 48 9889 6 L NIL NIL 3 1.52 49.7 21.8 N N 11.6 mrm 10 Y 100 90 70 350 Y 7 N
41 mary 48 1366 5 R NIL NIL 4 1.48 43.6 19.12 N N 10.6 mrm 8 Y 200 130 120 650 Y 10 N
42 selvi 42 1789 4 R NIL Y 2 1.47 59.4 25.71 N N 12.6 mrm 11 Y 160 170 130 730 Y 11 N
43 saroja 58 1843 9 R Y NIL 8 1.52 57.6 24.93 Y N 10.6 mrm 14 Y 190 180 200 1050 Y 15 Y
44 tamilarasi 40 1014 6 L NIL NIL 4 1.56 55 20.13 N N 10.2 mrm 16 Y 150 160 140 720 Y 11 N
45 narayani 50 1204 4 L Y NIL 3 1.57 70 28.4 N N 11 mrm 11 Y 180 170 150 930 Y 16 Y
46 rani 60 1459 7 L Y NIL 4 1.4 45 18.2 Y N 12.2 mrm 12 Y 120 110 70 400 Y 7 N
47 thangammal 45 2274 3 L NIL NIL 5 1.5 52 23.11 N N 10.6 mrm 14 Y 130 110 100 450 Y 7 N
48 varalakshmi 37 1034 1 R NIL NIL 3 1.55 57.9 23.6 N N 11.2 mrm 10 Y 140 130 90 425 Y 7 N
49 muniammal 50 1293 7 L Y Y 6 1.47 57 26.38 Y N 10.2 mrm 12 Y 180 170 190 780 Y 15 Y
50 vijaya 49 1355 5 L NIL NIL 3 1.49 56 25.3 N N 11.6 mrm 16 Y 160 110 90 500 Y 8 N
